| abstract |
the invention provides anti-CSPG4 CAR molecules and their use in treating, preventing, or ameliorating cancers that express CSPG4. In various embodiments, a chimeric antigen receptor (CAR) is provided comprising: an extracellular domain that comprises: a) an CSPG4 antibody or antigen binding fragment thereof that binds one or more epitopes of CSPG4 expressed on a cell; b) a transmembrane domain; c) one or more intracellular co-stimulatory signaling domains; and/or d) a primary signaling domain. In various embodiments, a method of generating an immune effector cell comprising a CAR is provided. |